Pfizer's, Merck's revenue disappoint investors

In this article:

Sales of Pfizer's blockbuster drug Ibrance zoomed higher but missed forecasts. Sales of Merck's cancer drug Keytruda catapulted higher, but overall revenue disappointed Wall Street. Fred Katayama reports.

Advertisement